The COVID-19 pandemic has significantly brought about a substantial transformation in stroke care, marked by a reduction in the number of patient visits, delayed medical consultations, and a decrease in the utilization of recombinant tissue plasminogen activator intravenous therapy and mechanical thrombectomy. The gene discussed is PLAT; the disease is stroke disorder.